[en] In the last years, the management of left valvular disease has considerably evolved. The American guidelines of 1998 were recently reviewed. Since this year, we have European guidelines which are different in some points. The place of exercise testing in risk stratification of asymptomatic valvular disease is increasing and helps to make earlier decision regarding the need for surgery.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Davin, Laurent ; Centre Hospitalier Universitaire de Liège - CHU > Cardiologie
PIERARD, Luc ; Centre Hospitalier Universitaire de Liège - CHU > Cardiologie
Lancellotti, Patrizio ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Language :
French
Title :
Nouveautes dans la prise en charge des valvulopathies du coeur gauche
Alternative titles :
[en] Update in the Management of Left Valvular Disease
* Iung B, Baron G, Butchart EG, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J 2003;24:1231-43.
** Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The task force on the management of valvular heart disease of the European society of cardiology. Eur Heart J 2007;28:230-68.
Pellikka PA, Sarano ME, Nishimura RA, et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 2005;111:3290-5.
Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur Heart J 2005;26:1309-13.
Lancellotti P, Lebois F, Simon M, et al. Prognostic importance of quantitative exercise Doppler echocardiography in asymptomatic valvular aortic stenosis. Circulation 2005;112:1377-82.
Lancellotti P, Karsera D, Lebois F, Tumminello G, Pierard LA. Determinants of an abnormal response to exercise in asymptomatic patients with severe aortic stenosis. Eur J Echo 2007; in press.
Bergler-Klein J, Klaar U, Heger M, et al. Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 2004;109:2302-8.
Lim P, Monin JL, Monchi M, et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: Role of B-type natriuretic peptide. Eur Heart J 2004;25:2048-53.
Monin JL, Quere JP, Monchi M, et al. Low-gradient aortic stenosis: Operative risk stratification and predictors for long-term outcome: A multicenter study using dobutamine stress hemodynamics. Circulation 2003;108:319-24.
* Pierard LA, Lancellotti P. Stress testing in valve disease. Heart 2007;93:766-72.
Lancellotti P, Troisfontaines P, Toussaint AC, Pierard LA. Prognostic importance of exercise-induced changes in mitral regurgitation in patients with chronic ischemic left ventricular dysfunction. Circulation 2003;108:1713-7.
Pierard LA, Lancellotti P. The rofe of ischemic mitral regurgitation in the pathogenesis of acute pulmonary edema. N Engl J Med 2004;351:1627-34.
Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005;352:2389-97.
Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007;49:554-61.
** Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of cardiovascular anesthesiologists endorsed by the Society for cardiovascular angiography and interventions and the Society of thoracic surgeons. J Am Coll Cardiol 2006;48:e1-148.
Monin JL, Dehant P, Roiron C, et al. Functional assessment of mitral regurgitation by transthoracic echocardiography using standardized imaging planes diagnostic accuracy and outcome implications. J Am Coll Cardiol 2005;46:302-9.
Enriquez-Sarano M, Schaff HV, Orszulak TA, et al. Valve repair improves the outcome of surgery for mitral regurgitation. A multivariate analysis. Circulation 1995;91:1022-8.
Detaint D, Messika-Zeitoun D,Avierinos JF, et al. B-type natriuretic peptide in organic mitral regurgitation: Determinants and impact on outcome. Circulation 2005;111:2391-7.
Rosenhek R, Rader F, Klaar U, et al. Outcome of watchful waiting in asymptomatic severe mitral regurgitation. Circulation 2006;113:2238-44.
Herrmann HC, Rohatgi S, Wasserman HS, et al. Mitral valve hemodynamic effects of percutaneous edge-to-edge repair with the MitraClip device for mitral regurgitation. Catheter Cardiovasc Interv 2006;68: 821-8.
Grayburn PA. Vasodilator therapy for chronic aortic and mitral regurgitation. Am J Med Sci 2000;320:202-8.
Bax JJ, Braun J, Somer ST, et al. Restrictive annuloplasty and coronary revascularization in ischemic mitral regurgitation results in reverse left ventricular remodeling. Circulation 2004;110:11103-8.
Grigioni F, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: Long-term outcome and prognostic implications with quantitative Doppler assessment. Circulation 2001;103:1759-64.
Breithardt OA, Sinha AM, Schwammenthal E, et al. Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure. J Am Coll Cardiol 2003;41:765-70.
Lancellotti P, Melon P, Sakalihasan N, et al. Effect of cardiac resynchronization therapy on functional mitral regurgitation in heart failure. Am J Cardiol 2004;94:1462-5.
Soler-Soler J, Galve E.Worldwide perspective of valve disease. Heart 2000;83:721-5.
Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutaneous balloon dilatation of the mitral valve: An analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988;60:299-308.
Iung B, Garbarz E, Michaud P, et al. Late results of percutaneous mitral commissurotomy in a series of 1024 patients. Analysis of late clinical deterioration: Frequency, anatomic findings, and predictive factors. Circulation 1999;99:3272-8.
Lev EI, Sagie A, Vaturi M, et al. Value of exercise echocardiography in rheumatic mitral stenosis with and without significant mitral regurgitation. Am J Cardiol 2004;93:1060-3.
Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777-802.
Dujardin KS, Enriquez-Sarano M, Schaff HV, et al. Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation 1999;99:1851-7.
Borer JS, Hochreiter C, Herrold EM, et al. Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance. Circulation 1998;97:525-34.
Chaliki HP, Mohty D,Avierinos JF, et al. Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation 2002;106:2687-93.
Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Aortic regurgitation complicated by extreme left ventricular dilation: Long-term outcome after surgical correction. J Am Coll Cardiol 1996;27:670-7.
Silverman DI, Gray J, Roman MJ, et al. Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. J Am Coll Cardiol 1995;26:1062-7.
Davies RR, Gallo A, Coady MA, et al. Novel measurement of relative aortic size predicts rupture of thoracic aortic aneurysms. Ann Thorac Surg 2006;81:169-77.
Evangelista A, Tornos P, Sambola A, Permanyer-Miralda G, Soler-Soler J. Long-term vasodilator therapy in patients with severe aortic regurgitation. N Engl J Med 2005; 353:1342-9.
Yetman AT, Bornemeier RA, McCrindle BW. Usefulness of enalapril versus propanolol or atenolol for prevention of aortic dilation in patients with the Marfan syndrome. Am J Cardiol 2005;95:1125-7.